We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-20 of 243 results
  1. A Brief Review of Gepants

    Purpose of Review

    Gepants are small molecules that antagonize calcitonin gene-related peptide (CGRP) receptors. Due to their favorable side effect...

    Diana Li, Jessica Abreu, Stewart J. Tepper in Current Pain and Headache Reports
    Article 02 August 2023
  2. Update of Gepants in the Treatment of Chronic Migraine

    Purpose of Review

    Despite the unmet therapeutic needs of patients with chronic migraine (CM) and/or medication overuse, available treatment options...

    Soohyun Cho, Byung-Kun Kim in Current Pain and Headache Reports
    Article 01 September 2023
  3. Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study

    Introduction

    The introduction of clacitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) has revolutionized the treatment of migraines. In...

    Taoufik Alsaadi, Reem Suliman, ... Yazan Bader in Neurology and Therapy
    Article Open access 15 February 2024
  4. Gepants — a long way to cure: a narrative review

    Calcitonin gene-related peptide (CGRP) is probably the most potent vasodilator in cerebral circulation. Forty years after its discovery, the new...

    Claudia Altamura, Nicoletta Brunelli, ... Fabrizio Vernieri in Neurological Sciences
    Article 02 June 2022
  5. What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?

    In this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies....

    Marta Waliszewska-Prosół, Doga Vuralli, Paolo Martelletti in The Journal of Headache and Pain
    Article Open access 05 December 2023
  6. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis

    Objective

    While there are several trials that support the efficacy of various drugs for migraine prophylaxis against placebo, there is limited...

    Christian Lampl, Antoinette MaassenVanDenBrink, ... Simona Sacco in The Journal of Headache and Pain
    Article Open access 19 May 2023
  7. Mode and site of action of therapies targeting CGRP signaling

    Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs...

    Alejandro Labastida-Ramírez, Edoardo Caronna, ... Jan Hoffmann in The Journal of Headache and Pain
    Article Open access 11 September 2023
  8. The Role of Step Therapy in the Treatment of Migraine

    Purpose of Review

    This review examines recent evidence and applies bioethical principles to evaluate the benefits and risks of using step therapy in...

    Leon S. Moskatel, Niushen Zhang in Current Pain and Headache Reports
    Article 05 August 2023
  9. Is the right way to go in between?

    In the study by Johnston et al., gepants were meant to be taken to treat emergent migraine. It is tempting to speculate what the effect would be if...

    Andreas R. Gantenbein, Andreas Kleinschmidt in The Journal of Headache and Pain
    Article Open access 30 March 2023
  10. Cardiovascular Disease and Migraine: Are the New Treatments Safe?

    Purpose of Review

    The authors present data on cardiovascular safety for the new acute and preventive migraine treatments including ditans, gepants,...

    Jennifer Robblee, Lauren K. Harvey in Current Pain and Headache Reports
    Article 25 June 2022
  11. CGRP-targeted medication in chronic migraine - systematic review

    Background

    Chronic migraine is a highly debilitating condition that is often difficult to manage, particularly in the presence of medication overuse...

    Renato Oliveira, Raquel Gil-Gouveia, Francesca Puledda in The Journal of Headache and Pain
    Article Open access 05 April 2024
  12. Migraine: from pathophysiology to treatment

    Migraine is an extremely disabling, common neurological disorder characterized by a complex neurobiology, involving a series of central and...

    Francesca Puledda, Elisa Martins Silva, ... Peter J. Goadsby in Journal of Neurology
    Article Open access 08 April 2023
  13. Unmet Needs in the Acute Treatment of Migraine

    Migraine represents the most common neurologic disorder, ranking second among the world’s causes of disability [expressed as years lived with...

    Enrico Bentivegna, Silvia Galastri, ... Paolo Martelletti in Advances in Therapy
    Article Open access 09 November 2023
  14. Acute Treatment of Migraine: Expert Consensus Statements from the United Arab Emirates (UAE)

    Introduction

    Migraine, characterized by recurrent headaches and often accompanied by other symptoms like nausea, vomiting, and sensitivity to light...

    Taoufik Alsaadi, Deeb M. Kayed, ... Suhail Al-Rukn in Neurology and Therapy
    Article Open access 19 January 2024
  15. Outpatient Approach to Resistant and Refractory Migraine in Children and Adolescents: a Narrative Review

    Purpose of Review

    Migraine is one of the top reasons for consulting a pediatric neurologist. Although the majority of children and adolescents who...

    Alison Marshall, Rebecca Lindsay, ... Serena L. Orr in Current Neurology and Neuroscience Reports
    Article 26 August 2022
  16. Drug Safety in Episodic Migraine Management in Adults Part 1: Acute Treatments

    Purpose of Review

    The aim of this review is to aid in choosing safe options when assessing potential risks of acute migraine treatments based on known...

    Yulia Y. Orlova, Sandhya Mehla, Abigail L. Chua in Current Pain and Headache Reports
    Article 10 May 2022
  17. A Review of Calcitonin Gene-Related Peptide and Its Implications for Vestibular Disorders

    Purpose of review

    Calcitonin gene-related peptide (CGRP) is an inflammatory neuropeptide widely present throughout the body and involved in many...

    Richard Baron, Kristen K. Steenerson in Current Treatment Options in Neurology
    Article 23 May 2024
  18. Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review

    The monoclonal antibodies (mAbs) blocking the calcitonin-gene related peptide (CGRP) pathway, collectively called here “anti-CGRP/rec mAbs”, have...

    Jean Schoenen, Annelies Van Dycke, ... Koen Paemeleire in The Journal of Headache and Pain
    Article Open access 01 August 2023
  19. Drug Safety in Episodic Migraine Management in Adults. Part 2: Preventive Treatments

    Purpose of Review

    The aim of this review is to aid in decision-making when choosing safe and effective options for preventive migraine medications.

    ...
    Abigail L. Chua, Sandhya Mehla, Yulia Y. Orlova in Current Pain and Headache Reports
    Article 19 May 2022
  20. Migraine

    Migraine is a common, chronic, disorder that is typically characterized by recurrent disabling attacks of headache and accompanying symptoms,...

    Michel D. Ferrari, Peter J. Goadsby, ... David W. Dodick in Nature Reviews Disease Primers
    Article 13 January 2022
Did you find what you were looking for? Share feedback.